RxDoctor Payments Data

Akriti Dewanwala, MD

Gastroenterology · Melbourne, FLNPI 1356573984

Payments from drug & device makers

$2,607in general payments, 2019–2025

Across 108 payments — averaging $24.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$759
  • Takeda Pharmaceuticals U.S.A., Inc.$297
  • Johnson & Johnson$220
  • Phathom Pharmaceuticals, Inc.$202
  • AstraZeneca$173
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$114
  • plus $842 from 16 others

What the payments were for

  • Food & beverage$2,607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,607 in reported general payments places this provider in the 40th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$126,341
Medicare patients
415
Services billed
936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide37$34,284
CreonLipase/Protease/Amylase20$26,816
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates147$9,250
Sucralfate51$4,897
Omeprazole235$3,672
Ursodiol12$1,995
Famotidine95$1,911
Pantoprazole Sodium82$1,058
Lactulose31$941
Esomeprazole Magnesium11$658
Metoclopramide Hcl46$499
ConstuloseLactulose11$358
Propranolol Hcl15$269
Dicyclomine Hcl14$234
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$759$61,10157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →